POOL / REUTERS
–
UNITED STATES – The American health authorities gave this Friday, April 23 the green light for the resumption of vaccination with Johnson & Johnson’s serum in the United States, suspended on April 13 after rare cases of thrombosis.
“The use of Janssen’s Covid-19 vaccine is expected to resume in the United States,” the Centers for Disease Control and Prevention (CDC) and the US drug agency, the FDA, said in a statement. that the benefits of the vaccine outweighed the risks in people 18 years of age and older.
The break in the use of the vaccine developed by the American laboratory had been decided to investigate several cases of women who developed serious cases of blood clots in association with low levels of platelets after their injection.
“The FDA and CDC are confident that this vaccine is safe and effective in preventing Covid-19,” the two agencies said.
“For now, the available data suggests that the risk of ‘thrombosis’ is very low, but the FDA and CDC will remain vigilant and will continue to investigate this risk,” according to the text.
Health care personnel administering the vaccine as well as those receiving it “should review the vaccine fact sheet,” which has been updated to include information on the risk of this syndrome, which has been updated. is produced in a very small number of people who have received the Janssen vaccine ”.
Earlier this Friday, experts from the American health authority had recommended the resumption of vaccination with Johnson’s serum.
The company’s scientific director, Paul Stoffels, said he was “grateful” for the decision of the experts, according to him “an essential step towards the continuation of urgently needed vaccinations, in a safe environment, for millions of people. in the USA”.
8 million doses already administered
The Johnson & Johnson vaccine has already been given to 7.98 million people in the United States.
According to data presented on Friday, out of 3.99 million women vaccinated, 15 developed severe cases of blood clots, and three died.
Thirteen of them were under 50 years old, the other two were between 50 and 64 years old. There have been no known cases in vaccinated men.
Some experts notably highlighted this Friday the benefits of this single-dose vaccine, which can be stored in refrigerators and more easily reach vulnerable groups, faced with the very rare risks of thrombosis, which can have devastating neurological consequences even when they are not. not fatal.
“It would be detrimental to do away with a vaccine that can be given as a single dose and that has the preference of the Hispanic community,” said Dr. Jose Romero, head of the expert committee.
The J&J vaccine has been shown to be 66% effective in preventing moderate to severe forms of Covid-19, according to clinical trials conducted on approximately 40,000 people aged 18 or over in several countries around the world.
Even though the link with the vaccine has not been demonstrated, scientists consider it to be the “probable cause” of the phenomenon of thrombosis, also detected with the AstraZeneca vaccine.
Johnson & Johnson and AstraZeneca technology uses an adenovirus as a vector, such as the Russian Sputnik V and Chinese CanSino vaccines.
Also to see sure The HuffPost: Castex, Véran and Blanquer did not skimp to reassure on AstraZeneca
–
